Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX), Henry Schein (HSIC) and Geron (GERN)
Tectonic Therapeutic Price Target Announced at $65.00/Share by Raymond James
Raymond James Initiates Tectonic Therapeutic(TECX.US) With Buy Rating, Announces Target Price $65
Tectonic Therapeutic Initiated With an Outperform at Raymond James
Wells Fargo Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Maintains Target Price $79
Wells Fargo Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Raises Target Price to $79
Tectonic Therapeutic Is Maintained at Outperform by Leerink Partners
Tectonic Therapeutic Analyst Ratings
Leerink Partners Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Raises Target Price to $69
Leerink Partners Raises Tectonic Therapeutic's Price Target to $69 From $49, Outperform Rating Maintained
Tectonic Therapeutic: Promising Phase 1a Results and Strong Financial Health Justify Buy Rating
TD Cowen Maintains Tectonic Therapeutic(TECX.US) With Buy Rating
TD Cowen Maintains Tectonic Therapeutic(TECX.US) With Buy Rating
TD Cowen Sticks to Their Buy Rating for Tectonic Therapeutic (TECX)
TD Cowen Maintains Tectonic Therapeutic(TECX.US) With Buy Rating
Piper Sandler Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Maintains Target Price $76
TD Cowen Maintains Tectonic Therapeutic(TECX.US) With Buy Rating
Piper Sandler Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Maintains Target Price $76
Piper Sandler Sticks to Their Buy Rating for Tectonic Therapeutic (TECX)
Wells Fargo Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Maintains Target Price $55